Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Receivables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Receivables for 3 consecutive years, with $67000.0 as the latest value for Q4 2025.

  • For Q4 2025, Receivables fell 54.11% year-over-year to $67000.0; the TTM value through Dec 2025 reached $67000.0, down 54.11%, while the annual FY2025 figure was $67000.0, 54.11% down from the prior year.
  • Receivables hit $67000.0 in Q4 2025 for Artiva Biotherapeutics, down from $79000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.8 million in Q4 2023 and bottomed at $30000.0 in Q2 2025.
  • Average Receivables over 3 years is $559500.0, with a median of $190000.0 recorded in 2024.
  • On a YoY basis, Receivables climbed as much as 54.11% in 2025 and fell as far as 97.95% in 2025.
  • Artiva Biotherapeutics' Receivables stood at $1.8 million in 2023, then tumbled by 91.7% to $146000.0 in 2024, then tumbled by 54.11% to $67000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $67000.0, $79000.0, and $30000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.